Health Care • Biotechnology: Pharmaceutical Preparations
$2.67 ▲ +0.13
(+5.12%)
MKT CAP: $277.4M • VOL: 1.03M
52W L $2 52W H $6
ROARABLE / RQD
D • 50/100
PIOTROSKI
2 / 9
LRMR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$172.5M | -$90.9M | -$41.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$165.7M | -$80.6M | -$36.9M |
| EBITDA (Normalized) | -$172.4M | -$90.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$113.2M | -$70.8M | -$33.5M |
| Capital Expenditures (CapEx) | $91.0K | $515.0K | — |
| Free Cash Flow (FCF) | -$113.3M | -$71.3M | -$33.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $85.4M | $33.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $78.1M | $171.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LRMR.